MRNA and BNTX Related Headlines
Go Back- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- BioNTech drops 10% on mRNA trial failure, highlighting Moderna contrast
- A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
- JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms
- US Judge blocks Trump Admin cuts to number of routinely recommended vaccines for children - Reuters
- US vaccine advisers drop plan to question mRNA COVID shots, WaPo reports
- BioNTech sues Moderna for U.S. patent infringement over covid vaccine MNEXspike - Court filing
- FDA may add black box warning to Covid-19 vaccines, CNN says
- FDA intends to put most serious warning on COVID vaccines, CNN reports
- FDA probes deaths likely related to COVID vaccines across age groups
- FDA probe of alleged deaths tied to Covid shots includes adults
- FDA Probe Of Alleged Deaths Tied To Covid Shots Includes Adults
- Shares of vaccine makers drop after FDA memo flags reports of child deaths
MRNA and BNTX Related Press Releases
Go Back- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
